Sean N Avedissian, Ying Mu, Caitlyn McCarthy, Ronald J Bosch, Serena Spudich, Rajesh T Gandhi, Deborah K McMahon, Joseph J Eron, John W Mellors, Jiajun Liu, Anthony T Podany, Courtney V Fletcher
{"title":"Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluid.","authors":"Sean N Avedissian, Ying Mu, Caitlyn McCarthy, Ronald J Bosch, Serena Spudich, Rajesh T Gandhi, Deborah K McMahon, Joseph J Eron, John W Mellors, Jiajun Liu, Anthony T Podany, Courtney V Fletcher","doi":"10.1002/phar.70013","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>HIV has been shown to persist in the central nervous system (CNS) in persons on antiretroviral therapy (ART). Our objective was to use pharmacokinetic (PK) modeling to estimate cerebrospinal fluid (CSF) exposure from time-variant concentrations of various antiretrovirals of ART regimens and to standardize CSF metrics, including maximum concentration [C<sub>MAX</sub>], area under the curve [AUC], and trough [C<sub>Trough</sub>].</p><p><strong>Methods: </strong>Advancing Clinical Therapeutics Globally (ACTG) A5321 is a prospective cohort study of HIV-1 reservoirs in persons with HIV. Plasma and CSF antiretroviral (ARV) concentrations were measured in 74 participants who were receiving ART. PK modeling (Pmetrics) was performed for nine ARVs. Relative CSF penetration for each ARV was estimated by comparing CSF C<sub>MAX</sub> and AUC to plasma C<sub>MAX</sub> and AUC (i.e., C<sub>MAXmethod</sub> and AUC<sub>method</sub>). The CSF C<sub>Trough</sub> for each ARV was compared with in vitro literature values of HIV inhibitory concentration values (IC<sub>50, 90, or 95</sub>).</p><p><strong>Results: </strong>Emtricitabine exhibited the highest median relative CSF penetration (C<sub>MAXmethod</sub>, 46.3%; AUC<sub>method</sub>, 72%) and dolutegravir had the lowest CSF penetration (C<sub>MAXmethod</sub>, 0.57%; AUC<sub>method</sub>, 0.57%). Tenofovir, lamivudine, atazanavir, and raltegravir had median estimated CSF C<sub>Trough</sub> concentrations less than IC<sub>50, 90, or 95</sub>. Interparticipant variability of relative CSF penetration based on exposures ranged from 160% for lamivudine to approximately 9% for dolutegravir.</p><p><strong>Conclusions: </strong>PK modeling successfully standardized ARV CSF concentrations to a given time point (i.e., C<sub>MAX</sub> or C<sub>Trough</sub>) to allow estimation of CSF penetration. This approach provides uniformity for the assessment of exposure, for the estimation of whether desired therapeutic drug goals are obtained in the CSF, and for further studies to investigate whether CSF exposure metrics calculated using this method are associated with measures of HIV persistence.</p>","PeriodicalId":20013,"journal":{"name":"Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/phar.70013","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: HIV has been shown to persist in the central nervous system (CNS) in persons on antiretroviral therapy (ART). Our objective was to use pharmacokinetic (PK) modeling to estimate cerebrospinal fluid (CSF) exposure from time-variant concentrations of various antiretrovirals of ART regimens and to standardize CSF metrics, including maximum concentration [CMAX], area under the curve [AUC], and trough [CTrough].
Methods: Advancing Clinical Therapeutics Globally (ACTG) A5321 is a prospective cohort study of HIV-1 reservoirs in persons with HIV. Plasma and CSF antiretroviral (ARV) concentrations were measured in 74 participants who were receiving ART. PK modeling (Pmetrics) was performed for nine ARVs. Relative CSF penetration for each ARV was estimated by comparing CSF CMAX and AUC to plasma CMAX and AUC (i.e., CMAXmethod and AUCmethod). The CSF CTrough for each ARV was compared with in vitro literature values of HIV inhibitory concentration values (IC50, 90, or 95).
Results: Emtricitabine exhibited the highest median relative CSF penetration (CMAXmethod, 46.3%; AUCmethod, 72%) and dolutegravir had the lowest CSF penetration (CMAXmethod, 0.57%; AUCmethod, 0.57%). Tenofovir, lamivudine, atazanavir, and raltegravir had median estimated CSF CTrough concentrations less than IC50, 90, or 95. Interparticipant variability of relative CSF penetration based on exposures ranged from 160% for lamivudine to approximately 9% for dolutegravir.
Conclusions: PK modeling successfully standardized ARV CSF concentrations to a given time point (i.e., CMAX or CTrough) to allow estimation of CSF penetration. This approach provides uniformity for the assessment of exposure, for the estimation of whether desired therapeutic drug goals are obtained in the CSF, and for further studies to investigate whether CSF exposure metrics calculated using this method are associated with measures of HIV persistence.
期刊介绍:
Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.